Japan Clinical Oncology Next Generation Sequencing Market Size & Outlook
Japan clinical oncology next generation sequencing market, 2018-2030 (US$M)
Related Markets
Japan clinical oncology next generation sequencing market highlights
- The Japan clinical oncology next generation sequencing market generated a revenue of USD 21.2 million in 2022 and is expected to reach USD 77.9 million by 2030.
- The Japan market is expected to grow at a CAGR of 17.6% from 2023 to 2030.
- In terms of segment, targeted sequencing and resequencing was the largest revenue generating technology in 2022.
- Whole Genome Sequencing is the most lucrative technology segment registering the fastest growth during the forecast period.
Clinical oncology next generation sequencing market data book summary
| Market revenue in 2022 | USD 21.2 million |
| Market revenue in 2030 | USD 77.9 million |
| Growth rate | 17.6% (CAGR from 2022 to 2030) |
| Largest segment | Targeted sequencing and resequencing |
| Fastest growing segment | Whole Genome Sequencing |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing and Resequencing |
| Key market players worldwide | Illumina Inc, Thermo Fisher Scientific Inc, Roche, Agilent Technologies Inc, Myriad Genetics Inc, PerkinElmer, Roche Holding AG, Pacific Biosciences of California Inc, Oxford Nanopore Technologies PLC, Paradigm Healthcare, Eurofins Scientific SE, Qiagen NV |
Other key industry trends
- In terms of revenue, Japan accounted for 5.7% of the global clinical oncology next generation sequencing market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China clinical oncology next generation sequencing market is projected to lead the regional market in terms of revenue in 2030.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 77.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Clinical Oncology Next Generation Sequencing Market Scope
Clinical Oncology Next Generation Sequencing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan clinical oncology next generation sequencing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical oncology next generation sequencing market will help companies and investors design strategic landscapes.
Targeted sequencing and resequencing was the largest segment with a revenue share of 72.64% in 2022. Horizon Databook has segmented the Japan clinical oncology next generation sequencing market based on whole genome sequencing, whole exome sequencing, targeted sequencing and resequencing covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Japan clinical oncology next generation sequencing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan clinical oncology next generation sequencing market databook
-
Our clientele includes a mix of clinical oncology next generation sequencing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan clinical oncology next generation sequencing market, including forecasts for subscribers. This country databook contains high-level insights into Japan clinical oncology next generation sequencing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan clinical oncology next generation sequencing ngs market size, by technology, 2018-2030 (US$M)
Japan Clinical Oncology Next Generation Sequencing Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
